Ein Schokoriegel von Nestlé.
Dienstag, 05.12.2017 17:35 von GlobeNewswire | Aufrufe: 173

Nestlé extends consumer healthcare portfolio by agreeing to acquire Atrium Innovations

Ein Schokoriegel von Nestlé. pixabay.com

Nestlé S.A. / Nestlé extends consumer healthcare portfolio by agreeing to acquire Atrium Innovations . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.


This press release is also available in Français (pdf) and Deutsch (pdf)


.............

 


Vevey, 5 December 2017

Nestlé extends consumer healthcare portfolio by agreeing to acquire Atrium Innovations

Nestlé today announced that it agreed to acquire privately-held Atrium Innovations, a global leader in nutritional health products, from a group of investors led by Permira Funds for USD 2.3 billion in cash. Atrium's 2017 sales are expected to reach almost USD 700 million.

The move supports Nestlé's pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories. The transaction is expected to close in the first quarter of 2018 following the completion of customary approvals and closing conditions.

Upon closing, Atrium, with its corporate offices in Quebec, Canada, will become part of Nestlé Health Science. Its existing management team will continue to manage the business, led by Peter Luther, Atrium Innovations President and Chief Executive Officer.

Greg Behar, Nestlé Health Science Chief Executive Officer said: "We value Atrium's history as a highly successful company and welcome its 1,400 employees to the Nestlé family. Their brands are a natural complement to our Consumer Care portfolio, which offers nutritional solutions in the areas of Healthy Aging, Healthy Growing, Gut Health and Obesity Care. Atrium's portfolio will extend our product range with value-added solutions such as probiotics, plant-based protein nutrition, meal replacements and an extensive multivitamin line, enabling consumers to address their health and wellness goals."

Behar added, "Atrium's established brands are in attractive categories and have the potential for continued strong growth as part of Nestlé through category, channel and geographic expansion. It also represents additional offerings in the segment for non-GMO, organic and natural supplements, a fast-growing consumer trend, as well as a new sales channel."


ARIVA.DE Börsen-Geflüster

Werbung

Weiter abwärts?

Kurzfristig positionieren in Nestlé SA
ME52FR
Ask: 1,07
Hebel: 6,67
mit moderatem Hebel
Zum Produkt
Smartbroker
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME52FR,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.

Kurse

91,84 CHF
-2,28%
Nestlé SA Chart

Peter Luther said: "Since Atrium was established in 1999, we have been dedicated to providing premium-quality, science-based, professionally recognized products to consumers and healthcare practitioners. We are very pleased to be joining Nestlé Health Science as we share a common purpose of helping people lead healthier lives by providing good-for-you products made with the highest standards for quality and efficacy. Nestlé will provide Atrium with the resources to accelerate the growth of our brands and reach more people globally."

Atrium's largest brand, Garden of Life®, is the #1 brand in the natural supplement industry in the U.S. Garden of Life, headquartered in Palm Beach Gardens, Florida, manufactures certified organic, non-GMO supplements that are sold in more than 14,000 health food stores and online in the U.S., as well as select markets internationally.

Pure Encapsulations® is a full line of hypoallergenic, research-based dietary supplements, and is the #1 recommended brand in the U.S. practitioner market. Pure Encapsulations, headquartered in Sudbury, Massachusetts, product line is free from common food allergens, GMOs, fillers, binders and artificial colors and is sold in the U.S. via healthcare practitioners, online as well as in pharmacies in several markets in Europe.

The remainder of the Atrium portfolio includes strong specialty brands like Wobenzym®, Douglas Laboratories®, Genestra Brands(TM), Orthica®, AOV®, Minami®, Klean Athlete®, Pharmax and Trophic(TM).




Contacts:

Media: Robin Tickle Tel.: +41 21 924 22 00
Investors: Steffen Kindler Tel.: +41 21 924 35 09





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nestlé S.A. via Globenewswire

--- End of Message ---

Nestlé S.A.
Avenue Nestlé 55 Vevey Switzerland

WKN: 887208;ISIN: CH0038863350;


Werbung

Mehr Nachrichten zur Nestlé SA Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News